hVIVO to Present at the Canaccord Genuity 36th Annual Growth Conference

(firmenpresse) - LONDON, UNITED KINGDOM -- (Marketwired) -- 08/04/16 -- hVIVO plc (AIM: HVO), the pioneer of human disease models, today announced that it will be presenting at the Canaccord Genuity 36th Annual Growth Conference in Boston, on Wednesday, August 10, 2016 at 1:30 p.m. ET.

A live audio webcast of the presentation will be available in the section of the hVIVO website at . A webcast replay will be available on the website for 90 days following the live presentation.



About hVIVO

hVIVO plc ("hVIVO") is a life sciences company pioneering a technology platform of human disease models to accelerate drug discovery and development in respiratory and infectious diseases, including flu, RSV, asthma and common cold. hVIVO has commercialised four disease models, successfully enrolled more than 2,000 subjects and conducted over 45 product validation studies for a wide range of industry, government and academic clients and collaborators. For more information, please visit , , and .



For further information, please contact:
hVIVO plc
+44 207 756 1300

Kym Denny
Chief Executive Officer
Graham Yeatman
Chief Financial & Business Officer

Media Enquiries
+44 203 021 3933 / +44 7854 979 420

Colin Paterson
Director of Marketing, Communication and Public Relations

Numis Securities Limited
+44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: Marketwired
Datum: 04.08.2016 - 20:30 Uhr
Sprache: Deutsch
News-ID 487453
Anzahl Zeichen: 0

contact information:
Town:

LONDON, UNITED KINGDOM

Kategorie:

Biotech

Diese Pressemitteilung wurde bisher 218 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"hVIVO to Present at the Canaccord Genuity 36th Annual Growth Conference"
steht unter der journalistisch-redaktionellen Verantwortung von

HVIVO PLC (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

hVIVO to Present at the 2016 BIO Investor Forum ...

LONDON, UNITED KINGDOM -- (Marketwired) -- 10/13/16 -- hVIVO plc (AIM: HVO), a specialty biopharma company with clinical testing capabilities, today announced that it will be presenting at the 2016 BIO Investor Forum in San Francisco on Tuesday, Oct ...

hVIVO Landmark Asthma Stratification Initiative, Supporting Targeted Therapy Dev ...

LONDON, UNITED KINGDOM -- (Marketwired) -- 09/02/16 -- (AIM: HVO), the pioneer of human disease models, is delighted to announce that the Company's landmark asthma stratification initiative is now underway, with the first volunteer inoculated ...

Alle Meldungen von HVIVO PLC